https://orcid.org/0000-0001-5669-3502
References
- Litchfield K , ReadingJL , PuttickCet al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell184(3), 596–614; e514 (2021).
- Mcgrail DJ , PiliePG , RashidNUet al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol.32(5), 661–672 (2021).
- De Bortoli T , BenaryM , HorakPet al. Tumour mutational burden and survival with molecularly matched therapy. Eur. J. Cancer190, 112925 (2023).
- Offin M , RizviH , TenetMet al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin. Cancer Res.25(3), 1063–1069 (2019).
- Lin C , ShiX , ZhaoJet al. Tumor mutation burden correlates with efficacy of chemotherapy/targeted therapy in advanced non-small cell lung cancer. Front Oncol.10, 480 (2020).
- Smith AE , FerraroE , SafonovAet al. HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat. Commun.12(1), 6667 (2021).
- Hyman DM , Piha-PaulSA , WonHet al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature554(7691), 189–194 (2018).
- Taber A , ChristensenE , LamyPet al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun.11(1), 4858 (2020).
- Lengel HB , MastrogiacomoB , ConnollyJGet al. Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell41(5), 970–985; e973 (2023).
- Tsang ES , CsizmokV , WilliamsonLMet al. Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration. NPJ Precis. Oncol.7(1), 31 (2023).
- Batalini F , GulhanDC , MaoVet al. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clin. Cancer Res.28(21), 4714–4723 (2022).
- Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov.12(1), 31–46 (2022).
- Neyret-Kahn H , FontugneJ , MengXYet al. Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks. Oncogene42(19), 1524–1542 (2023).
- Labrie M , BruggeJS , MillsGB , ZervantonakisIK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat. Rev. Cancer22(6), 323–339 (2022).
- Zhou Q , ZhangXC , ChenZHet al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J. Clin. Oncol.29(24), 3316–3321 (2011).